<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>14</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>5663</FirstPage>
			<LastPage>5667</LastPage>
			<ELocationID EIdType="pii">31310</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Earlier studies on the association between p53 codon 72 Arg&gt;Pro polymorphism and cancerrisk were inconclusive and conflicting for the Saudi population. Therefore, we performed a meta-analysis toinvestigate the relationship between the codon 72 Arg&gt;Pro polymorphism and overall cancer risk in SaudiArabia. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: We searched all eligible published studies and data were pooled together toperform the meta-analysis. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculatedfor homozygous, heterozygous, dominant and recessive genetic models. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: A total of five eligible publishedstudies covering 502 cancer cases and 784 healthy controls were included in the meta-analysis. No publicationbias was detected in this study. The results suggested that the variant (Pro vs Arg: p=0.960; OR=1.004, 95%CI=0.852-1.183), homozygous (Pro.Pro vs Arg.Arg: p=0.970; OR=1.006, 95% CI=0.729-1.390), heterozygous(Arg.Pro vs Arg.Arg: p=0.473; OR=0.783, 95% CI=0.402-1.527) carriers were not associated with overall cancerrisk. Similarly, dominant (Pro.Pro+Pro.Arg vs Arg.Arg: p=0.632; OR=0.886, 95% CI=0.540-1.454) and recessive(Pro.Pro vs Pro.Arg+Arg.Arg: p=0.269; OR=1.163, 95%CI=0.890-1.521) models also did not indicate increasedrisk of cancer. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: The current meta-analysis suggests that the codon 72 Arg&gt;Pro polymorphism ofthe p53 gene might not contribute to cancer susceptibility in Saudi population. Future well designed large casecontrol studies are needed to validate our findings.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Meta-analysis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">p53 polymorphism</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Saudi Arabia</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_31310_69b8631bf65bfc2e328af783ca6f4fab.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
